Dyslipidemia Secondary to Hypothyroidism and Cholestasis
| Autor: | Saavedra, A, Rodrigues, E, Carvalho, D |
|---|---|
| Přispěvatelé: | Instituto de Investigação e Inovação em Saúde |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Diabetes Mellitus / diagnosis
Dyslipidemias / drug therapy Cholestasis / complications dislipidemias Autoimmune Diseases / drug therapy lcsh:Medicine Hypothyroidism / drug therapy Atorvastatin / therapeutic use Hypothyroidism / diagnosis colestase Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use Hypothyroidism / complications lcsh:R5-920 cirrose hepática biliar lcsh:R nutritional and metabolic diseases Middle Aged Obesity / complications Thyroxine / therapeutic use Withholding Treatment Female lipids (amino acids peptides and proteins) lcsh:Medicine (General) Liver Cirrhosis Biliary / complications Autoimmune Diseases / diagnosis Dyslipidemias / etiology hipotiroidismo |
| Zdroj: | Acta Médica Portuguesa, Vol 33, Iss 3, Pp 204-207 (2020) |
| ISSN: | 1646-0758 |
| Popis: | In about 28% of patients, dyslipidemia has a secondary cause. Many times, the treatment of these causes can lead to the total correction of dyslipidemia. We describe the case of a 50-year-old female patient with class II obesity and primary biliary cirrhosis, evaluated for mixed dyslipidemia with poor control (statins and fibrates were being administered) as well as abnormal liver tests. The investigation carried out revealed primary auto-immune hypothyroidism. After normalisation of thyroid function by treatment with levothyroxine, as well as suspending the administration of statins and fibrates, there was an improvement in the lipid profile, although hypercholesterolemia continued. During this time, the patient was diagnosed with diabetes and she re-commenced statin therapy (atorvastatin 10 mg), which resulted in a normal lipid profile being achieved. In this case, the authors set out to highlight the importance of excluding secondary causes of dyslipidemia - including hypothyroidism, and then go on to discuss particular aspects of statin therapy for liver disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|